Axogen (AXGN)

Healthcare · Medical Devices
$36.13 -0.14% on the day Market cap $2.0B 52-week range $15.27 to $52.91 Prices as of Oct 11, 2026

What the price implies

A reverse DCF: instead of guessing a fair value, it asks what growth today's price already assumes. How it works.

Axogen's free cash flow was negative in fiscal 2025, so a cash-flow reverse DCF doesn't give a meaningful answer. The Modeling tab works from revenue and margins instead.

Fundamental grade

F

Five factors scored 1 to 9 from AXGN's latest numbers, weighted into one grade. It describes the business, not whether the stock is a buy.

Valuation2
Profitability2
Growth4
Financial health9
Cash efficiency0

Results from SEC filings

Fiscal years, from Axogen's 10-K filings. Ten years of the full income statement, balance sheet and cash flow.

Fiscal year20212022202320242025
Revenue$127M$139M$159M$187M$225M
Net income-$27M-$29M-$22M-$10M-$16M
Free cash flow-$41M-$36M-$20M$1M-$3M
EPS (diluted)-$0.65-$0.69-$0.51-$0.23-$0.34
Operating margin-20.0%-21.4%-13.5%-1.8%-3.5%

Where the revenue comes from

Revenue by regions, fiscal 2025. Every breakdown, year by year.

U.S.$222M99%
International$3M1%

Superinvestors who own AXGN

From each investor's latest 13F filing (what a 13F shows). 3 of the investors we track hold it.

InvestorLast quarterValue% of portfolioQuarter
Ron Baron
Baron Capital (BAMCO)
Added $34M0.05%Q2 2026
Jean-Marie Eveillard
First Eagle Investment Management
Trimmed $16M0.03%Q2 2026
Cliff Asness
AQR Capital Management
Added $980,0120.0%Q2 2026

Insider buying

Open-market purchases by Axogen's executives and directors in the last 12 months, from SEC Form 4 filings. What insider buying tells you.

No open-market insider purchases of AXGN in the last 12 months. Most insider activity is selling and option exercises, which aren't shown here.

Get an alert at your buy price

Pick the price you'd be interested at. We'll email you when AXGN trades at or below it.

$

New accounts get 7 days of Pro, price alerts included. No card needed.

In the full deep dive

DCF fair value per share
Yearly return (IRR) at today's price
Growth implied by revenue and margins
15+ years of statements and quarters

Questions

Are Axogen insiders buying the stock?

No open-market insider purchases of AXGN in the last 12 months, according to SEC Form 4 filings.

Which superinvestors own Axogen?

3 of the superinvestors Investingly tracks hold AXGN in their latest 13F, including Ron Baron, Jean-Marie Eveillard, Cliff Asness.

Prices and ratios as of Oct 11, 2026; statements from SEC filings. Information only, not investment advice. Superinvestor holdings come from 13F filings, which are filed up to 45 days after each quarter ends.